Precipio Launches ICE COLD-PCR Liquid Biopsy Kit for Pancreatic Cancer

Specialty diagnostics company Precipio (NASDAQ:PRPO), today announced the launch of two additional ICEme kits using its proprietary ICE-COLD PCR liquid biopsy technology. The new RUO kits enable the detection of mutations in KRAS Exons 2 & 3, which include important predictive and prognostic biomarkers, and are available on both qPCR and Sanger molecular diagnostic platforms.

As quoted in the press release:

The ICP kits will be priced at approximately $100 per specimen, a fraction of competing liquid biopsy tests. Laboratories running ICP can apply tier-1 approved codes to bill for the tests at approximately $400 (based on Medicare’s 2018 Clinical Lab Fee Schedule).

The breakthrough clinical value of this dramatic cost reduction is the ability to test sequentially and repeatedly, increasing the likelihood of identifying the KRAS mutation soon after it appears. This enables the physician to optimize treatment in real time, and react to the genetic signals that may precede potential patient deterioration.

Click here to read the full press release.